Your browser doesn't support javascript.
loading
Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.
Shi, Yun; Kerry, Philip S; Nanson, Jeffrey D; Bosanac, Todd; Sasaki, Yo; Krauss, Raul; Saikot, Forhad K; Adams, Sarah E; Mosaiab, Tamim; Masic, Veronika; Mao, Xianrong; Rose, Faith; Vasquez, Eduardo; Furrer, Marieke; Cunnea, Katie; Brearley, Andrew; Gu, Weixi; Luo, Zhenyao; Brillault, Lou; Landsberg, Michael J; DiAntonio, Aaron; Kobe, Bostjan; Milbrandt, Jeffrey; Hughes, Robert O; Ve, Thomas.
Afiliação
  • Shi Y; Institute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
  • Kerry PS; Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
  • Nanson JD; School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
  • Bosanac T; Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA.
  • Sasaki Y; Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
  • Krauss R; Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA.
  • Saikot FK; School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
  • Adams SE; Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
  • Mosaiab T; Institute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
  • Masic V; Institute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
  • Mao X; Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
  • Rose F; Institute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
  • Vasquez E; Institute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
  • Furrer M; Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany.
  • Cunnea K; Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
  • Brearley A; Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
  • Gu W; School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
  • Luo Z; School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
  • Brillault L; Centre for Microscopy and Microanalysis, The University of Queensland, Brisbane, Australia.
  • Landsberg MJ; School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
  • DiAntonio A; Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Developmental Biology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
  • Kobe B; School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
  • Milbrandt J; Needleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
  • Hughes RO; Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA. Electronic address: rhughes@disarmtx.com.
  • Ve T; Institute for Glycomics, Griffith University, Southport, QLD 4222, Australia. Electronic address: t.ve@griffith.edu.au.
Mol Cell ; 82(9): 1643-1659.e10, 2022 05 05.
Article em En | MEDLINE | ID: mdl-35334231
ABSTRACT
The NADase SARM1 (sterile alpha and TIR motif containing 1) is a key executioner of axon degeneration and a therapeutic target for several neurodegenerative conditions. We show that a potent SARM1 inhibitor undergoes base exchange with the nicotinamide moiety of nicotinamide adenine dinucleotide (NAD+) to produce the bona fide inhibitor 1AD. We report structures of SARM1 in complex with 1AD, NAD+ mimetics and the allosteric activator nicotinamide mononucleotide (NMN). NMN binding triggers reorientation of the armadillo repeat (ARM) domains, which disrupts ARMTIR interactions and leads to formation of a two-stranded TIR domain assembly. The active site spans two molecules in these assemblies, explaining the requirement of TIR domain self-association for NADase activity and axon degeneration. Our results reveal the mechanisms of SARM1 activation and substrate binding, providing rational avenues for the design of new therapeutics targeting SARM1.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas do Domínio Armadillo / NAD Idioma: En Revista: Mol Cell Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas do Domínio Armadillo / NAD Idioma: En Revista: Mol Cell Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália